SCHEMBL4715010

SCHEMBL4715010

O=C(O)c1cn(C2CC2)c2c(Cl)cc(F)cc2c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
CYP1A2 P05177 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
TOP2A P11388 8/20 0.56
TOP2B Q02880 8/20 0.56
ALDH1A1 P00352 4/20 0.55
POLB P06746 2/20 0.55
OPRM1 P35372 2/20 0.55
CHRM2 P08172 1/20 0.55
CHRM1 P11229 1/20 0.55
OPRD1 P41143 1/20 0.55
KCNH2 Q12809 4/20 0.48
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 1/20 0.47
CYP2C9 P11712 1/20 0.47
PRKD3 O94806 1/20 0.46
ALOX15 P16050 1/20 0.46
CLK2 P49760 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Heptane SCHEMBL8861899 0.91 KDM4E (0.52) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL5443905 0.87 TOP2A (0.61) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL4714330 0.85 KDM4E (0.52) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL29473541 0.85 KDM4E (0.52) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL4714327 0.85 KDM4E (0.52) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL6217925 0.85 TOP2A (0.61) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL4713233 0.85 KDM4E (0.60) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL6217009 0.84 ALDH1A1 (0.60) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL10582892 0.82 KDM4E (0.52) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B
SCHEMBL8521029 0.82 TOP2A (0.61) KDM4ECYP1A2SMN1; SMN2TOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1262477-B1 ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT DAIICHI SANKYO CO LTD (JP) 2008-09-03 EP claimed
US-20030119848-A1 Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-06-26 US claimed
EP-1262477-A1 ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-12-04 EP claimed
US-20230218726-A1 TREATMENT OF VIRAL CONJUNCTIVITIS OKOGEN, INC. 2023-07-13 US disclosed
EP-4138882-A1 TREATMENT OF VIRAL CONJUNCTIVITIS Okogen, Inc. (US) 2023-03-01 EP disclosed
EP-1262477-B1 ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT DAIICHI SANKYO CO LTD (JP) 2008-09-03 EP disclosed
US-7176313-B2 Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-13 US disclosed
US-20030119848-A1 Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-06-26 US disclosed
EP-1262477-A1 ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-12-04 EP disclosed
CN-1044118-C 7-isoindolinyl-quinolone derivatives and process for their preparation BAYER AG (DE) 1999-07-14 CN disclosed
CN-1189494-A Substituted isoazalene compound BAYER AG (DE) 1998-08-05 CN disclosed
US-5250705-A Salt formation with tartaric acid; treatment with base; deprotection SHIONOGI & CO., LTD. (JP) 1993-10-05 US disclosed
EP-0487030-A2 Process of optical resolution for the preparation of an optically active cyclic amine SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1992-05-27 EP disclosed
EP-0226961-B1 5-AMINO AND 5-HYDROXY-6,8-DIFLUOROQUINOLONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1991-06-12 EP disclosed
US-4977154-A 7-PIPERAZINE DERIVATIVES WARNER-LAMBERT COMPANY (US) 1990-12-11 US disclosed
EP-0226961-A1 5-Amino and 5-hydroxy-6,8-difluoroquinolones as antibacterial agents WARNER-LAMBERT COMPANY (US) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119848-A1 Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient PGD, PPA1, FASTKD1 KDM4E 3677/4885CYP1A2 2156/4885SMN1; SMN2 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.